Balance Sheet Intellia Therapeutics, Inc.
Equities
NTLA
US45826J1051
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.53 USD | +2.10% |
|
+5.24% | +73.03% |
| Mar. 06 | Nektar Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) | RE |
| Mar. 03 | Intellia Therapeutics Presents Longer-Term Clinical Data For Lonvoguran Ziclumeran | CI |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||
Cash And Equivalents | 123M | 524M | 227M | 189M | 155M | |||||
Short Term Investments | 625M | 669M | 685M | 412M | 294M | |||||
Total Cash And Short Term Investments | 749M | 1.19B | 912M | 602M | 450M | |||||
Accounts Receivable, Total | 2.03M | 3.77M | 36.46M | 8.52M | 9.47M | |||||
Total Receivables | 2.03M | 3.77M | 36.46M | 8.52M | 9.47M | |||||
Prepaid Expenses | 18.58M | 20.41M | 47.55M | 29.83M | 68.36M | |||||
Restricted Cash | - | - | - | - | - | |||||
Other Current Assets, Total | - | - | 2.1M | - | - | |||||
Total Current Assets | 769M | 1.22B | 998M | 640M | 528M | |||||
Gross Property Plant And Equipment | 126M | 194M | 188M | 296M | 182M | |||||
Accumulated Depreciation | -26.11M | -33.2M | -39.86M | -49.69M | -58.61M | |||||
Net Property Plant And Equipment | 100M | 161M | 148M | 247M | 124M | |||||
Long-term Investments | 420M | 127M | 136M | 287M | 178M | |||||
Other Long-Term Assets, Total | 4.76M | 15.73M | 18.08M | 17.39M | 13.08M | |||||
Total Assets | 1.29B | 1.52B | 1.3B | 1.19B | 842M | |||||
Liabilities | ||||||||||
Accounts Payable, Total | 9.65M | 5.15M | 7.45M | 14.59M | 20.25M | |||||
Accrued Expenses, Total | 43.31M | 60.88M | 60.13M | 55.36M | 49.86M | |||||
Current Portion of Leases | 9.11M | 16.68M | 18.6M | 20.25M | 26.48M | |||||
Unearned Revenue Current, Total | 63.76M | 43.84M | 22.14M | 20.66M | 7.29M | |||||
Other Current Liabilities | - | - | 6.89M | - | - | |||||
Total Current Liabilities | 126M | 127M | 115M | 111M | 104M | |||||
Long-Term Leases | 64.91M | 114M | 96.75M | 190M | 66.85M | |||||
Unearned Revenue Non Current | 63.48M | 19.93M | 38.85M | 18.26M | - | |||||
Other Non Current Liabilities | - | 24.03M | - | - | - | |||||
Total Liabilities | 254M | 285M | 251M | 319M | 171M | |||||
Common Stock, Total | 7K | 9K | 9K | 10K | 12K | |||||
Additional Paid In Capital | 1.75B | 2.42B | 2.71B | 3.05B | 3.26B | |||||
Retained Earnings | -703M | -1.18B | -1.66B | -2.18B | -2.59B | |||||
Comprehensive Income and Other | -2.63M | -7.46M | -2.26M | 605K | 1.03M | |||||
Total Common Equity | 1.04B | 1.24B | 1.05B | 872M | 671M | |||||
Total Equity | 1.04B | 1.24B | 1.05B | 872M | 671M | |||||
Total Liabilities And Equity | 1.29B | 1.52B | 1.3B | 1.19B | 842M | |||||
Supplemental Items | ||||||||||
ECS Total Shares Outstanding on Filing Date | 74.67M | 88.02M | 96.11M | 104M | 118M | |||||
ECS Total Common Shares Outstanding | 74.49M | 87.1M | 93M | 102M | 116M | |||||
Book Value / Share | 13.97 | 14.19 | 11.29 | 8.55 | 5.77 | |||||
Tangible Book Value | 1.04B | 1.24B | 1.05B | 872M | 671M | |||||
Tangible Book Value Per Share | 13.97 | 14.19 | 11.29 | 8.55 | 5.77 | |||||
Total Debt | 74.02M | 131M | 115M | 210M | 93.33M | |||||
Net Debt | -1.01B | -1.13B | -897M | -652M | -512M | |||||
Debt Equivalent Oper. Leases | 130M | 180M | 267M | 300M | 515M | |||||
Equity Method Investments, Total | 58.13M | 32.46M | 11.76M | - | - | |||||
Account Code - Inventory Valuation | 3 | 3 | 3 | 3 | 3 | |||||
Machinery, Total | 43.34M | 56.33M | 67.58M | 71.97M | 71.16M | |||||
Full Time Employees | 485 | 598 | 526 | 403 | 377 |
Select your edition
All financial news and data tailored to specific country editions
















